NCT Number,Study Title,Study URL,Acronym,Study Status,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Age,Phases,Study Type,Study Design,Other IDs,Study Documents
NCT03476616,Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients,https://beta.clinicaltrials.gov/study/NCT03476616,HEVRO,UNKNOWN,NO,Hypertension|Obesity,DRUG: Eplerenone (-based therapy) arm|DRUG: Valsartan (-based therapy) arm,"Difference in change of ABPM from baseline, in the eplerenone arm versus the valsartan arm as monotherapy at 8 weeks, as combined dual treatment with amlodipine at 16 weeks and as combined triple treatment with amlodipine and indapamide at 24 weeks., Ambulatory blood pressure measurements (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of mean ambulatory systolic and diastolic blood pressure measurements between baseline and each time frame in all participants, 8, 16 and 24 weeks","Difference in change of office BP from baseline, in the eplerenone arm versus the valsartan arm as monotherapy at 8 weeks, as combined dual treatment with amlodipine at 16 weeks and as combined triple treatment with amlodipine and indapamide at 24 weeks., Office blood pressure measurements (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of office systolic and diastolic blood pressure measurements between baseline and each time frame in all participants, 8, 16 and 24 weeks","Difference in frequency of controlled hypertension (mean ABPM < 130/80 mm Hg) between the study arms at 8, 16 and 24 weeks., Ambulatory blood pressure monitoring (metric unit: mmHg) at baseline and 8,16 and 24 weeks and evaluation of the difference of mean ambulatory systolic and diastolic blood pressure measurements between baseline and each time frame in all participants, 8, 16 and 24 weeks",Hippocration General Hospital,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,,
NCT04746495,Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA),https://beta.clinicaltrials.gov/study/NCT04746495,ENOVA,WITHDRAWN,NO,Hypertension,DRUG: Placebo|DRUG: Eplerenone 50mg,"Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) Cycle threshold (Ct) value of mineralocorticoid receptor-regulated gene messenger ribonucleic acid (mRNA), Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR., Week 6 (after first study treatment)|RT-qPCR Ct value of mineralocorticoid receptor-regulated gene mRNA, Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR., Week 12 (after second study treatment)",,,University of Michigan,"National Heart, Lung, and Blood Institute (NHLBI)","ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE",HUM00170418|1K23HL128909-01A1,
NCT05593055,"Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension",https://beta.clinicaltrials.gov/study/NCT05593055,,NOT_YET_RECRUITING,NO,Hypertension|Left Ventricular Hypertrophy,DRUG: Eplerenone|DRUG: Chlorthalidone|DRUG: Potassium,"Change in myocardial flow reserve, Change in myocardial flow reserve (ratio of hyperemic stress myocardial blood flow to rest myocardial blood flow), 9 months","Change in myocardial external efficiency, Change in myocardial external efficiency (ratio of myocardial work to oxygen consumption), 9 months",,Brigham and Women's Hospital,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE",2022P002126,
NCT04519164,"Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity",https://beta.clinicaltrials.gov/study/NCT04519164,,RECRUITING,NO,Metabolic Syndrome|Hypertension|Overweight and Obesity,DRUG: Eplerenone|DRUG: Chlorthalidone with potassium chloride,"Change in stress myocardial perfusion reserve on cardiac MRI, Change in myocardial perfusion, one year","Change in extracellular volume fraction on cardiac MRI, change in myocardial fibrosis, one year",,Brigham and Women's Hospital,,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",2020P002311,
NCT04968184,Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe CKD,https://beta.clinicaltrials.gov/study/NCT04968184,Clarion-CKD,RECRUITING,NO,Chronic Kidney Diseases,DRUG: Placebo|DRUG: KBP-5074,"Change in seated trough cuff SBP from baseline to Week 12, Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, will be evaluated., From baseline to Week 12|Change in seated trough cuff SBP from Week 48 to Week 52, Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, will be evaluated., Week 48 to Week 52","Change in seated trough cuff SBP from baseline to Week 24, Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, will be evaluated., From baseline to Week 24|Changes in seated trough cuff diastolic blood pressure (DBP) from baseline to Week 12 and Week 24, Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated., From baseline to Week 12 and Week 24|Changes in seated trough cuff SBP and DBP from baseline to Week 48, Effect of KBP-5074 on SBP and DBP by assessing change in seated trough cuff SBP and DBP, will be evaluated., From baseline to Week 48|Changes in urinary albumin: creatinine ratio (UACR) from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline, Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated., From baseline to Week 12 and Week 24|Percentage changes in UACR from baseline to Week 12 and Week 24 for participants with UACR ≥30 mg/g at baseline, Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, will be evaluated., From baseline to Week 12 and Week 24|Changes in UACR from baseline to Week 12, Week 24, and Week 48, Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated., From baseline to Week 12, Week 24, and Week 48|Percentage changes in UACR from baseline to Week 12, Week 24, and Week 48, Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated., From baseline to Week 12, Week 24, and Week 48|Change in seated trough cuff DBP from Week 48 to Week 52, Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, will be evaluated., Week 48 to Week 52|Change in UACR from Week 48 to Week 52, Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated., Week 48 to Week 52|Percentage change in UACR from Week 48 to Week 52, Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g, macroalbuminuria (defined as UACR ≥300 mg/g) and microalbuminuria (defined as UACR ≥30 and \<300 mg/g) at baseline, will be evaluated., Week 48 to Week 52|Number of participants with adverse events (AEs) and serious adverse events (SAEs), The safety and tolerability of KBP-5074,will be evaluated., Screening (Week -6 to -2) until EOS (Week 56) or Unscheduled visit or end of treatment or early termination",,KBP Biosciences,,"ADULT, OLDER_ADULT",PHASE3,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",KBP5074-3-001,
NCT05814770,Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism,https://beta.clinicaltrials.gov/study/NCT05814770,,NOT_YET_RECRUITING,NO,Primary Aldosteronism|Hypertension,DRUG: Finerenone|DRUG: Spironolactone,"Hypertension remission rate., The proportion of patients with blood pressure\<140/90 mmHg at 12 weeks., 12 weeks.","The change of systolic and diastolic BP from the baseline level., To compare the antihypertensive effect of finerenone versus spironolactone and to establish the noninferiority of finerenone by measuring the mean change from baseline to the week 16 endpoint in end- of-dose (trough) seated DBP., Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks.|Change of serum potassium level, Change of serum potassium level (mmol/L), Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks.|Changes of plasma renin activity and ARR., Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks.|Incidence of Treatment-Adverse Events as assessed by gynaecomastia, mastodynia, menstrual abnormalities, impotence, hyperkalemia and other adverse events., 1. Adverse effects such as gynaecomastia, mastodynia, menstrual abnormalities and impotence due to its agonist activity.
2. Hyperkalemia.
3. Other adverse events., Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks.|Proportion of patients with normal serum., Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks.",,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,National Key Research and Development Program of China|National Natural Science Foundation of China,"ADULT, OLDER_ADULT",PHASE4,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,PA2023,
